[High-dose melphalan in patients with multiple myeloma].
[High-dose melphalan in patients with multiple myeloma].
复制标题
多发性骨髓瘤患者的大剂量马法兰[J].
作者：
P. Moreau;M. Le Bonniec;J. Harousseau
自1983年以来，越来越多的临床试验在多发性骨髓瘤患者中使用高剂量美法仑，有或没有自体干细胞支持。研究表明，包括高剂量美法仑在内的高剂量治疗可被视为新诊断患者的治疗选择。本报告的目的是回顾和总结多发性骨髓瘤患者静脉注射大剂量美法仑的临床信息，并检查未来研究的潜在领域。
Since 1983 an increasing number of clinical trials have used high-dose melphalan with or without autologous stem cell support in patients with multiple myeloma. It has been shown that high-dose therapy including high-dose melphalan may be considered as the treatment of choice in newly diagnosed patients. The purpose of this report is to review and summarize the clinical information on IV high-dose melphalan in patients with multiple myeloma and to examine potential areas of future investigation.